🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Money slide to show comparison of adjuvant regimens for all cancer . From @asco #GU25 OncoAlert

Another nice slide by Maite Bourlon . Useful in clinics. Time off systemic therapy for major surgical intervention in advanced RCC . Note that Cabozantinib Needs to stop 3 weeks before surgery and Lenvatinib needs to stop one week before surgery. ASCO #GU25.

Atezo and pembro looking at Perioperative gastric cancer trial results with amusement, meanwhile durva chilling out with positive EFS 🙂 ONCO BRUNO

As part of Myeloma Awareness Month, IMAGe is organizing the MD/ DNB level quiz on 24 Mar (docs.google.com/forms/d/1P-UK3…) & DM/DrNB Meyloma Quiz on 25 Mar with exciting prizes (docs.google.com/forms/d/1rKAtO…)

🚨Thrilled to share our Burkitt lymphoma/leukemia study in Blood Cancer Journal. Massive effort(n=265) from Hematology Cancer Consortium. MTX & EPOCH protocols equally effective overall, but MTX outperforms in CSF+ & BM+ cases. Valuable insights for treatment decisions! nature.com/articles/s4140…

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

Advances in alveolar soft part sarcoma treatment in the era of immunotherapy - ESMO Rare Cancers ESMO - Eur. Oncology Dr Sameer Rastogi esmorarecancers.org/article/S3050-…

Doxorubicin–Trabectedin in Leiomyosarcoma | New England Journal of Medicine NEJM Sharing our correspondence for the LMS 04 article Annie K Baa nejm.org/doi/full/10.10…

Uncommon EGFR mutations in NSCLC often fly under the radar. This is one slide showing the first-line data for uncommon EGFR mutations — from 4 trials - ACHILLES, UNICORN, KCSG-lu15-09 , and CHRYSALIS-2 ( cohort C ) #oncotwitter #uncomonEGFR #LCSM OncoAlert Oncology Brothers

Some studies shows how we can reduce costs based on biomarkers SHORT-HER 9 weeks of trastuzumab is ✅ based TILS 20% or more TILs Working Group OncoAlert #oncoalertAF JAMA Oncology⤵️ jamanetwork.com/journals/jamao…

Our correspondence in The Lancet on the TRANSMET trial. Annie K Baa Amol Patel Jasmin Porwall thelancet.com/journals/lance…

KEYNOTE-689 Update at #AACR25 Neoadjuvant + adjuvant #pembrolizumab in resectable LA-HNSCC ✅ EFS HR: 0.73 (95% CI 0.58–0.92) ✅ Median EFS: 51.8 mo vs 30.4 mo ✅ CPS ≥10 subgroup: HR 0.66 (95% CI 0.49–0.88) ✅ 2-yr EFS: 75% vs 62% ✅ Early & sustained KM curve separation ✅

CDK4/6 Rechallenge Trials: What Works? What Fails? 📢 published in Journal of Clinical Oncology: PALMIRA Trial ❌ Rechallenging palbociclib post-progression shows no PFS benefit In contrast: 🟢 MAINTAIN → Switching to ribociclib improves PFS 🟢 postMONARCH → Switching to abemaciclib improves PFS

Real world data suggest that chemo (cape, eribulin, taxanes) outperforms a second topo1 ADC after progression on T-DXd. Key question to address in breast oncology (and across oncology fields!). #ESMOBreast25 #esmoambassadors

The #TolAlgorithm for treating HR+/HER2- MBC in (the first half of) 2025 Sara Tolaney #ESMOBreast25 #esmoambassadors

Carcinoma of Unknown Primary: Cancer without a past 🧬 Early dissemination 🛡️Immune editing of the primary 🧪CK20+, CDX2+, SATB2+ → treat colon-like 🧭Let biology, not anatomy, guide therapy Not a diagnostic failure — a metastatic strategy. nejm.org/doi/full/10.10… #ASCO25

When you treat metastatic CRPC in elderly person, polypharmacy and drug to drug interactions needs to noted . These are some common drug interactions with Abiraterone and Enzalutamide. Useful for clinical practice OncoAlert Kate Sears Oncology Brothers Yakup Ergün

#ESMOGI25 Starts tomorrow TALENTACE: TACE + Atezo + Bev vs TACE Alone in uHCC TACE-PFS: 11.3 vs 7 mo (HR: 0.71) PFS (RECIST v1.1): 10.3 vs 6.3 mo Grade 3-5 TRAEs: 63.8% vs 42.2% (EMERALD-1➡️15.0 vs 8.2 mo, HR:0.77) (LEAP-012: 14.6 vs 10.0 mo, HR:0.66)

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to: 🔹 Colorectal: +103% 🔹 Pancreatic: +100% 🔹 Esophageal: +86% 🔹 Liver: +81% 🌍 Biggest increases in Asia & Africa 💡 Call to action: Early detection, access, equity. Time for GI oncologist

Yüksel Ürün ASCO OncoAlert Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 The Lancet Advanced Prostate Cancer Consensus Conference LARVOL Arun Azad Emre Yekedüz Sumanta K. Pal, MD, FASCO Shilpa Gupta Vivek Subbiah, MD André P. Fay Andrey Soares silke gillessen Deborah Mukherji Dr Amol Akhade I worry that the majority of that benefit is being driven by BRCA and PLAB2. Is this going to be your 1L for all HRRm? Neeraj Agarwal, MD, FASCO Rana McKay, MD, FASCO Yakup Ergün PARPi have a good amount of side effects with very little benefit with certain HRR deficiencies. Love this slide by